Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 30, 2025

Stock market today: Dow, S&P 500, Nasdaq waver as Fed minutes show division over December rate cut

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq waver as Fed minutes show division over December rate cut US stocks wavered after the opening bell on Tuesday, as Wall Street looked to regroup after a tech-led slide to begin the final stretch of 2025…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Molina Healthcare has a clearer path to significant double-digit long-term growth than Apple.

    80% confidence
  • Tesla estimated Q4 deliveries at a 15% drop compared to the same period last year.

    80% confidence
  • Globally, supply on metals from lithium to cobalt has been heavily constrained by a mixture of government policy and natural resource decline, and mining companies have faced a mix of pressures including ESG policies, long permitting timelines, and self-imposed capital efficiency requirements following the commodity price bust in the 2010s.

    80% confidence
  • If federal budgetary actions push the market downward, Molina's shares could drop below $100, which he labeled a generational buy.

    80% confidence
  • We're in a metals war

    80% confidence
  • Most participants judged that further downward adjustments to the target range for the federal funds rate would likely be appropriate if inflation declined over time as expected.

    80% confidence
  • Michael Burry stated he would acquire Molina Healthcare if he had the funds.

    80% confidence
  • Metals and mining sector tailwinds should continue in early 2026, and the sector should outperform again as a result.

    80% confidence
  • Molina Healthcare has the best loss ratio, best expense ratio, best win rate, and most conservative accounting among insurers.

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,351 source documents archived
Query this data → isubstrate.com